CAS-ViewAlert

View Alert


		Versions:

Originator:	CMO Messaging
From:	CMO Messaging
Issue date:	Originally issued on 21-Feb-2024 13:57:16. This version was issued on 21-Feb-2024 13:57:16
This alert has been issued to:
	Care Trusts Mental Health Trusts Other contacts Specialists Trusts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Regional Offices Learning Disabilities Trusts Mental Health & Social Care Trusts Ambulance Trusts Social Care Providers (registered with CAS) Mental Health & Learning Disabilities Trusts Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health Director of Public Health Acute Trusts Community Trusts GP - Locum NHS 111 and Out of hours providers GP Practices Integrated Care Boards Community Pharmacy Primary Care Networks GP Practices 1
Action category:	Action
Title:	Valproate: important new regulatory measures for oversight of prescribing to new patients and existing female patients
Broadcast content:	The harmful effects of prenatal exposure to valproate are well documented. Following a review, the Commission on Human Medicines has recommended further restrictions to valproate use to reduce avoidable harm which were introduced by the MHRA in January. Please see the attached letter from Chief Medical Officers across the UK regarding the recently announced sodium valproate safety measures.
Additional information:	NHS England Regions: please cascade this notification to community pharmacy.
Alert reference:	CEM/CMO/2024/001
Attachments:	CEM_CMO_2024_001-.pdf